Background: Acute myeloid leukemia (AML) is a heterogeneous collection of leukemic disorders ranging from chemotherapy-sensitive subsets [inversion 16 and t(8;21)1, which often can be cured with cytosine arabinoside alone, to the most resistant subsets, which can survive even supralethal levels of combination alkylator chemotherapy (cytogenetic subsets monosomy 5 and monosomy 7). Materials and Methods: To analyze the expression of BCL-2 family genes, which are expressed in these subsets of AML, we used PCR sequence amplification reactions that are dependent on oligonucleotide primers representing the BHI and BH2 homology domains to generate the unique regions between BH1 and BH2. These
Introduction
Cytogenetic analysis of acute myeloid leukemia (AML) cells has been used to predict the respon-siveness of patients to induction chemotherapeutic regimens (1, 2) . AML patients whose leukemia cells contain inversion 16 or t(8;21) are more often than not sensitive to single-agent cytosine arabinoside treatment (3) (4) (5) (6) (7) (8) , whereas patients whose leukemia cells contain monosomy 5, monosomy 7, or trisomy 8 are resistant to even ablative levels of combination therapy (6) (7) (8) . The molecular changes associated with these chromosomal abnormalities are under intensive investigation (9) (10) (11) (12) . At the present time, the mechanisms of resistance or sensitivity are not completely understood.
Many neoplastic cells die by apoptosis when treated with DNA-damaging chemotherapeutic agents (13) . The BCL-2 family of genes has been shown to contain members that either induce or prevent the apoptosis process (14) (15) (16) . All of the BCL-2 gene family members share a high degree of amino acid sequence similarity in the BH1 and BH2 regions, which are separated by a unique sequence region of approximately 50 amino acid residues. It has been shown that the bcl-2, bcl-xl, and mcl proteins inhibit cell death, whereas the bax, and bcl-xs proteins promote cell death (14, (17) (18) (19) (20) . The BCL-2 family also includes recently identified genes such as BAD, BAK, BAG, the function of which remains to be tested (21) (22) (23) (24) (25) (26) .
Since the balance among the BCL-2 family members that inhibit or induce cell death appears to determine the survival of cells in certain circumstances (26) , we investigated the expression profile of individual BCL-2 members in AML cells from the chemotherapy-sensitive and -resistant cytogenetic subtypes of AML. We tested the ratio between pro-apoptosis transcripts and anti-apoptosis transcripts for a possible association between the expression of specific BCL-2 genes and the response to chemotherapy. We also attempted to isolate novel BCL-2 family members from AML cells. Nearly 250 individual bacterial colonies from these mini-libraries were picked and used to inoculate LB broth in 96-well tissue culture plates. The resulting bacterial cultures were subsequently blotted on nylon membrane in a slotblot apparatus. The identities of the DNA inserts in each bacterial colony were determined by carrying out hybridization with radioactive probes specific to known members of the BCL-2 gene family, such as bcl-2, bcl-x, bax, and mcl. The number of clones hybridized with respective probes were counted.
Materials and Methods

Cells
Upon further analysis, some of the clones that did not hybridize to any of the probes were found to contain no inserts of 1 50 bp. They were removed from the analysis. The composition of each mini-library was constructed by counting the number of colonies that hybridized with the major BCL-2 family members. The results of these analyses are shown in Figure 2 .
Bcl-2 appeared to be the most abundantly expressed member of the BCL-2 gene family in the poor-prognosis AML subsets associated with monosomy 5 and monosomy 7 karyotypes. Interestingly, nearly 50% of the DNA fragments amplified from AML cells of the good-prognosis, inversion 16 subset hybridized to a bcl-xlong probe. The bax subsets were represented equally among all subsets. No mcl homologous products were detected in any of the AML samples. In the control K562 cells, which contain the BCR-ABL fusion gene, all 50 clones tested were homologous to the bcl-xlong probe.
Examination of the Ratio between bcl-xlong and bcl-xshort Transcripts These two splicing variants of the bcl-x gene product are called bcl-xlong and bcl-xshort.
Since bcl-xlong is associated with resistance to apoptosis and bcl-xshort promotes apoptosis, it would be interesting to know the ratio between the two forms of bcl-x transcripts in the chemotherapy-sensitive and -resistant forms of AML, as they function in opposite ways for the regulation of cell death. The 5'-bcl and 3'-bcl primers used for the PCR reaction can only amplify the bclxlong cDNA; the BHI and BH2 regions are deleted in bcl-xshort mRNA. Therefore, we designed a separate pair of primers that are specific to bcl-x. The RT-PCR products of bcl-xlong and bcl-xshort appeared as DNA fragments of different sizes on agarose gels when these primers were used.
As shown in Figure 3 , bcl-xlong was expressed at a higher level than was bcl-xshort in samples from AML patients of the monosomy 5 and monosomy 7 subsets. In contrast, the ratio between bcl-xlong and bcl-xshort is lower in inversion 16 RT-PCR was carried out with total RNA as templates and bcl-x specific oligonucleotides as primers. The PCR products were separated by agarose gel electrophoresis, transfered to nylon membrane in alkaline solution and hybridized with radioactive probes derived from bcl-x cDNA. The filter was exposed to multiple X-ray films. The ratio between the bcl-xlong signal and bcl-xshort signals was calculated from the image intensity on the films.
samples from AML patients with good-prognosis cytogenetic markers.
Analysis Testing for Presence of Novel Genes that Belong to the bcl-2 Gene Family Thirty-two clones were identified from the AML PCR reactions, the products of which did not hybridize to the probes for known members of the BCL-2 family (bcl-2, bcl-x, bax, and mcl). These clones, however, were shown to contain 150 nucleotide unique sequence regions between the two BHI and BH2 homology regions. It is possible that these clones may contain sequences for previously unidentified members of the BCL-2 family. Plasmid DNA was therefore prepared from these products and used as a template in dideoxynucleotide sequencing reaction. The sequences were submitted to the GenBank databases for homology search by the BLAST programs. Two clones of particular interest were identified which we designated bclnl and bcln9. Bclnl contained sequences homologous to the polycystic kidney disease protein. No homology for the nucleic acid and peptide sequences of bcln9 was found after extensive search in various databases with all available algorithms. Fulllength cDNAs of bclnl and bcln9 are being obtained and are subject to further analysis.
Discussion
Leukemia cells collected from patients with AML show a variety of cytogenetic abnormalities. Some of these chromosomal aberrations are associated (inversion 16 and t(8;2 1)) with excellent response to chemotherapy. AML patients with karyotypes of inversion 16 or t(8;2 1) are very sensitive to cytosine arabinoside as a single agent. These cells may have an unusual sensitivity to cytosine arabinoside which may exceed that of the normal myeloid cells. On the other hand, cells from the AML patients of the monosomy 5 or monosomy 7 subtypes are notoriously resistant at diagnosis even to intensive systemic combination chemotherapy. Making the resistant cells respond to chemotherapeutic agents remains a challenge in the treatment of AML.
A number of studies suggested a role of the BCL-2 gene family in the regulation of chemoresistance in AML (13) . The BCL-2 family is an expanding group of genes that shares the highly conserved BH1 and BH2 domains. Members of the family that antagonize apoptosis include bcl-2, bcl-xl and mcl. The genes that facilitate cell death include bax, bcl-xshort, and bak. It has been shown that these gene products can form homo-or heterodimers with each other. The regulation of cell death is achieved in part by varying the ratio between the pro-and antiapoptosis members in the composition of the dimers, which can alter the sensitivity of the cells to DNA damaging agents.
We therefore tested the expression of the BCL-2 gene family members in AML cells with representative karyotypes of these good-and poor-prognosis subsets of AML. We were especially interested in the ratio among the expression of individual members. It was shown that the ratio between pro-and anti-apoptosis molecules is more important than the absolute amount of gene products in determining cellular susceptibility to apoptosis. We also looked for an association between the expression pattern and sensitivity to chemotherapy.
By using oligonucleotides representing the BH1 and BH2 domains, we were able to amplify all transcripts that contained BH1-BH2 intervening regions. Among them were known BCL-2 family member clones that may be associated with previously unidentified members of the BCL-2 gene family. We determined the ratio among various expression products by analyzing the composition of the PCR products and separating these products on a molecular weight gel. As shown in Figure 2 , bcl-2 appeared to be the most abundant member expressed in samples from the poor-prognosis AML group, whereas it was a minor component in samples from the good-prognosis group.
It has been reported that there was a significantly greater level of bcl-2 expression in cells from AML patients who failed to achieve remission after chemotherapy than in those who responded (27) . It was also shown that inhibition of bcl-2 with antisense oligonucleotides increased the sensitivity of AML blasts to cytosine arabinoside (28) . Our studies suggested that the higher level of bcl-2 expression may contribute to the poor response to chemotherapy observed in AML in patients whose leukemia cells have the monosomy 5 or monosomy 7 cytogenetic abnormality.
The molecular approach used in Figure 2 could not discriminate among the alternative splicing transcripts bcl-xshort from the bcl-xlong variant of the bcl-x gene. Higher levels of bclxlong expression could protect against apoptosis by bcl-xshort. We therefore examined the ratio between the two forms of bcl-x transcript by PCR amplification of bcl-x cDNA with a pair of bcl-xspecific primers. As shown in Figure 3 and Table 1 , the ratio between the anti-apoptotic bclxlong and the pro-apoptotic bcl-xshort is higher in cells from the chemoresistant subtypes than in cells from the chemosensitive subtypes. Bclxlong has been demonstrated to be able to confer resistance to a variety of cytotoxic drugs including cisplatin, etoposide, vincristine, and hygromycin B (29, 30) . We also noted that bcl-xlong appeared to be the single most abundant BCL-2 family member in the K562 cell line which is known to be resistant to many chemotherapeutic agents (Fig. 2) .
Our strategy of amplifying all cDNA-containing regions homologous to BH1 and BH2 domains offered an opportunity to test for the presence of or to isolate clones for new BCL-2 family members from AML cells. The clones shown in Figure 2 as "others" may include such members. Sequence analysis revealed that some of the clones seemed to come from less specific priming during PCR. The remaining clones represent cDNAs with previously unidentified functions. Their membership in the BCL-2 family and their involvement in the modulation of apoptosis will be determined in further analysis.
In summary, we studied the expression profiles of BCL-2 family members in AML cells from different cytogenetic and prognostic subgroups. Previous studies usually focused on the expression of individual members without looking at all members in one study. The results of our analysis suggest that an association exists between the ratio of anti-apoptotic to pro-apoptotic members of the BCL-2 gene family and the chemoresistance of AML cells. These observations may ultimately lead to molecular interventions in AML that are designed to sensitize the cells to chemotherapy.
